Retrospective analysis of newly recorded certifications of visual impairment due to diabetic retinopathy in Wales during 2007–2015 by Steve, Luzio & Becky, Thomas
 Cronfa -  Swansea University Open Access Repository
   
_____________________________________________________________
   
This is an author produced version of a paper published in:
BMJ Open
                              
   





Thomas, R., Luzio, S., North, R., Banerjee, S., Zekite, A., Bunce, C. & Owens, D. (2017).  Retrospective analysis of














This item is brought to you by Swansea University. Any person downloading material is agreeing to abide by the terms
of the repository licence. Copies of full text items may be used or reproduced in any format or medium, without prior
permission for personal research or study, educational or non-commercial purposes only. The copyright for any work
remains with the original author unless otherwise specified. The full-text must not be sold in any format or medium
without the formal permission of the copyright holder.
 
Permission for multiple reproductions should be obtained from the original author.
 




  1Thomas RL, et al. BMJ Open 2017;7:e015024. doi:10.1136/bmjopen-2016-015024
Open Access 
AbstrAct
Objective The aim of this study was to analyse the 
changes in new certifications for both sight impairment (SI) 
and severe sight impairment (SSI, blindness) in Wales due 
to diabetic retinopathy (DR)/maculopathy between 2007 
and 2015.
Research design and methods This is a retrospective 
analysis of annual data of new certifications for visual 
impairment and blindness (Certificate of Vision Impairment) 
for England and Wales derived from the national database 
provided by the Certifications Office, Moorfields Eye 
Hospital, over a period of 8 years from 2007.
Results In Wales there were 339 less new certifications 
for both SI and severe SSI from any cause combined 
from 2007–2008 to 2014–2015. The number SI and SSI 
combined specifically due to DR was reduced by 22 in 
people with known diabetes. This was a reduction in new 
certifications over the observation period from 82.4 to 
46.9 per 100 000 (−43.1%) with a fall in SSI from 31.3 
to 15.8 per 100 000 (−49.4%), respectively. During this 
observation period however, there was a parallel increase 
in 52 229 (39.8%) persons with diabetes in Wales.
Conclusions While acknowledging the limitations of 
the certification process and the increasing numbers of 
persons with diabetes, the incidence of SI and SSI per 
100 000 population of persons with diabetes in Wales has 
almost halved over an 8-year period up to 2015. This may 
reflect the earlier diagnosis of DR and sight-threatening 
DR since the introduction of screening and/or improved 
diabetes management with timely onward referral and 
newer treatments.
IntroductIon
In 2015, an estimated 415 million people 
worldwide had diabetes mellitus, with 
diabetic retinopathy (DR) among its most 
feared complications capable of causing 
visual impairment and blindness.1 There-
fore, the predicted global increase in 
diabetes prevalence to 642 million by 2040 
is of considerable public health concern 
due to its adverse effect on both the indi-
vidual concerned and society in general.2–4 
Previously, in 2012 a pooled meta-analysis 
was carried out including 35 studies world-
wide involving people with diabetes where 
DR was determined from retinal photo-
graphs estimated that 34.6% had evidence 
of any DR and with 10.2% having vision 
threatening DR.5 The prevalence of any DR 
in the Welsh population during 2005–2009 
was 32.4% with 29% non-sight-threatening 
DR and 3.4% sight-threatening DR.6 The 
increasing prevalence of diabetes is acknowl-
edged to represent a major public health 
problem worldwide and DR is among the 
most feared complications, leading to sight 
impairment (SI) and severe sight impair-
ment (SSI) if not detected and treated at an 
early stage, and is therefore prioritised on 
the global public health agenda.7 8 The soci-
etal costs of SI due to DR are significant and 
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Research
Strengths and limitations of this study
 ► A key limitation of our analysis is a consequence 
of the non-compulsory and inconsistent process 
of reporting/certification of visual loss (sight 
impairment and severe sight impairment) which 
currently requires a consultant ophthalmologist 
to complete a Certificate of Vision Impairment 
(CVI or CVI-W) rather than being population based 
compounded by the reluctance of patients to be 
registered as visually impaired/blind.
 ► The strength of our study relates to its nationwide 
coverage, unified data base, providing important 
epidemiological information on the trends in new 
certification of visual impairment due to diabetic 
retinopathy (DR) as the main cause, in Wales, over 
an 8-year period.
 ► An additional strength of this study is that the time 
period it covers is when a nationwide screening 
programme was introduced to reduce severe sight 
impairment (blindness) by the early detection and 
treatment of sight-threatening DR and second, raise 
awareness to the presence of DR when enhanced 
medical management can prevent progression.
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include severe reduction in quality of life, loss of produc-
tivity and increased healthcare costs.2 4 9
In its ‘Action plan for the prevention of avoidable 
blindness and visual impairment; 2009–2012’ the WHO 
has highlighted the importance of recording SI and SSI, 
in an attempt to monitor the impact of various strategies 
to eliminate preventable SI and SSI globally.8 Recording 
the number of people who are SSI in England and Wales 
was initiated in 1851, and between 1930 and 2003 a desig-
nated certificate (BD8) was employed which required 
the signature of an ophthalmologist with the cause of 
low vision included from 1950 onwards.10–15 The BD8 was 
superseded in 2005 by the Certificate of Vision Impair-
ment (CVI) for England and later in 2007 its equivalent 
for Wales (CVI-W) which are crown copyright under 
the ownership of the government. A copy of the CVI is 
sent to the Certification Office, London, for anonymised 
epidemiological analysis and which is funded by the 
Royal National Institute for the Blind operating under 
the governance of the Royal College of Ophthalmolo-
gists. Since 2012, despite their limitation, certification 
numbers have been used in an attempt to indicate the 
burden of preventable sight loss and which are included 
in the Public Health Outcomes Framework by the Depart-
ment of Health, UK Government. Between 1999 and 2000 
the major causes of SSI in working aged adults (between 
16 and 64 years) in England and Wales were DR/macu-
lopathy (17.7%), hereditary retinal diseases (15.8%) and 
optic atrophy (10.1%).16 17 However, in a more recent anal-
ysis for 2009–2010 the order of the three main causes of 
SSI had changed to hereditary retinal disorders (20.2%), 
DR/maculopathy (14.4%) and optic atrophy (14.1%).18 
DR was therefore, for the first time in five decades, no 
longer the leading cause of certifiable SSI in England and 
Wales, a most encouraging trend from a public health 
standpoint.
In Wales a screening programme for DR was launched 
in 2003 and by the end of 2006 all persons known to have 
diabetes in Wales, aged 12 years or over, and under the 
care of general practice located within Wales had been 
offered an appointment for screening. Therefore, the 
time period covered in this analysis corresponds with the 
time when screening was provided on a national basis 
implementing standardised quality assured methods to 
include photography and grading. This retrospective 
analysis was conducted in order to address whether the 
introduction of Diabetic Eye Screening in Wales (DESW) 
has had any impact on the level of certification for SI 
and SSI in Wales between 2007 and 2015 by virtue of the 
earlier detection of DR and its subsequent management.
Methods
numerator
The numerator included the causes of new CVI-W of both 
SI and SSI for Wales that were sourced from the Certi-
fications Office at Moorfields Eye Hospital, London. 
Details of data entry and transmission using the BD8 
certificate causes of blindness recorded by ophthalmol-
ogists and CVI forms have been reported previously.18 19 
All patients provided explicit consent for certification 
and for anonymised data to be sent to the Certifications 
Office. The number of new certifications of SI and SSI 
due to diabetic eye disease (retinopathy/maculopathy) 
included those cases where the main cause of certifiable 
SI or SSI was DR/maculopathy and those where the main 
cause was recorded as multiple conditions but a contribu-
tory cause was diabetic eye disease. To be certified as SSI, 
sight assessed using the Snellen chart, while wearing any 
glasses or contact lenses, will fall into the following cate-
gories: visual acuity (V/A) of less than 3/60 with a full 
visual field, or V/A between 3/60 and 6/60 with a severe 
reduction of field of vision, such as tunnel vision, or V/A 
of 6/60 or above but with a very reduced field of vision, 
especially if a lot of sight is missing in the lower part of the 
field. A definition of SI requires the sight to fall into one 
of the following categories, while wearing any glasses or 
contact lenses, a V/A of 3/60 to 6/60 with a full field of 
vision, or V/A of up to 6/24 with a moderate reduction of 
field of vision or with a central part of vision that is cloudy 
or blurry, or V/A of 6/18 or even better if a large part of 
the field of vision, a whole half of the vision, is missing or a 
lot of the peripheral vision is missing. Certification for SI 
or SSI is decided upon by a consultant ophthalmologist. 
Incidence data were provided for SI and SSI for each year 
running from April 2007 to March 2015 derived from the 
certifications for SI and SSI covering a 2-year period.
denominator
Annual population estimates for Wales were obtained 
from the Office of National Statistics and were based 
on the midyear estimates. Between 2007 and 2010 the 
estimates were adjusted to bring them into line with 
the official mid-2011 population estimates published in 
2013.20 The number of persons with diabetes in Wales is 
recorded annually by the Quality and outcomes Frame-
work (QoF) in primary care.21 QoF is a voluntary reward 
and incentive programme which aims to standardise 
improvement in the delivery of primary medical services. 
The estimate for the population with diabetes for the 
last period of the certification timescale was used as the 
denominator.
statistical analysis
The incidence of visual impairment (SI and SSI) due to 
any cause in Wales was calculated using the total number 
of new certifications and the population estimates for each 
yearly time period between 2007 and 2015. In addition, 
the incidence of SI and SSI related to DR was calculated 
using the QoF estimates of people with known diabetes 
in Wales. The results are represented as the combined 
total (SI plus SSI), SI and SSI individually when due to 
either any cause or DR in the population of Wales. The 
percentage change in the incidence of new certifications 
for SI and SSI due to any cause or DR during each of the 
eight annual observation periods was also calculated.
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Table 1 Number of new certifications for combined (total), SI and SSI due to any cause in the population of Wales 2007–2015
Visual impairment certifications due to any cause in Wales: n (per 100 000 population)
Time period Population Total SI SSI
2007–2008 3 025 867 1582 (52.3) 814 (26.9) 681 (22.5)
2008–2009 3 038 872 1737 (57.2) 914 (30.1) 777 (25.6)
2009–2010 3 049 971 1544 (50.6) 802 (26.3) 689 (22.6)
2010–2011 3 098 346 1425 (46.0) 745 (24.0) 649 (20.9)
2011–2012 3 074 067 1463 (47.6) 703 (22.9) 721 (23.5)
2012–2013 3 082 400 1362 (44.2) 696 (22.6) 621 (21.1)
2013–2014 3 092 000 1302 (42.1) 680 (22.0) 580 (18.8)
2014–2015 3 099 086 1243 (40.1) 631 (20.4) 568 (18.3)
SI, sight impairment; SSI, severe sight impairment.
Table 2 New certifications for SI and SSI due to DR in the population of Wales 2007–2015
Wales certifications due to DR: n (per 100 000 population)
Time period Population Total*  SI SSI
2007–2008 3 025 867 108 (3.6) 64 (2.1) 41 (1.4)
2008–2009 3 038 872 140 (4.6) 89 (2.9) 51 (1.7)
2009–2010 3 049 971 118 (3.9) 71 (2.3) 45 (1.5)
2010–2011 3 098 346 103 (3.3) 62 (2.0) 40 (1.3)
2011–2012 3 074 067 95 (3.1) 55 (1.8) 38 (1.2)
2012–2013 3 082 400 98 (3.2) 58 (1.9) 38 (1.2)
2013–2014 3 092 000 95 (3.1) 62 (2.0) 29 (0.9)
2014–2015 3 099 086 86 (2.8) 51 (1.6) 29 (0.9)
DR, diabetic retinopathy; SI, sight impairment; SSI, severe sight impairment.
*Total number of new certifications, this includes those of unknown category of SI or SSI.
results
Between 2007−2008 and 2014–2015 in Wales there was 
an overall reduction in new certifications for SI and SSI 
combined from any cause of 339, that is, from 1582 to 
1243, equivalent to 12.2 per 100 000 of the population 
representing a decrease of 21.4% over the 8-year obser-
vation period (table 1). The new certifications for SI fell 
by 24.2% from 26.9 (95% CI 25.1 to 28.8) per 100 000 
population in 2007–2008 to 20.4 (95% CI 18.8 to 22.0) 
per 100 000 in 2014–2015. For both parameters, a tempo-
rary and unexplainable increase was seen between 2008 
and 2009 after which there was a reduction year on year 
for the remainder of the study period. However, new 
certifications for SSI have fluctuated over the observa-
tion period with a peak at 2008–2009 of 25.6 (95% CI 
23.8 to 27.4) per 100 000 population followed by a lesser 
peak during 2011–2012 before reaching a nadir of 18.3 
(95% CI 16.9 to 19.9) per 100 000 during the final year 
compared with 22.5 (95% CI 20.9 to 24.3) per 100 000 
during the initial year period of 2007–2008.
The number of new certifications for SI and SSI 
combined in Wales due to DR during 2007–2008 
increased from 108 to a peak of 140 certifications during 
2008–2009. Thereafter, the numbers fell to 86 certifica-
tions during 2014–2015, a reduction of 20.4% from the 
initial period of 2007–2008 (table 2). Similarly, there was a 
temporary increase in both SI and SSI during the second 
annual period of observation with SI certifications there-
after falling consistently from 89 to 51 during 2014–2015 
a reduction of 42.7% and SSI falling from 51 to 29 certif-
icates being a fall of 43.1% over the remaining 7 years of 
the study. The overall reduction in SI and SSI combined, 
SI and SSI for the entire study period from 2007–2008 to 
2014–2015 was 22.2%, 23.8% and 35.7%, respectively. For 
the population of Wales the initial rate of new certifica-
tions in 2007–2008 for SI and SSI combined, SI and SSI 
was 3.6 (95% CI 3.0 to 4.3), 2.1 (95% CI 1.7 to 2.7) and 
1.4 (95% CI 1.0 to 1.8) per 100 000, respectively, followed 
by slight increase in the second year to 4.6 (95% CI 
3.9 to 5.4), 2.9 (95% CI 2.4 to 3.6) and 1.7 (95% CI 1.3 to 
2.2) per 100 000, respectively, and then a general trend 
downwards to the lowest rate of 2.8 (95% CI 2.2 to 3.4), 
1.6 (95% CI 1.3 to 2.2) and 0.9 (95% CI 0.7 to 1.3) per 
100 000, respectively, seen during 2014–2015.
Over the 8-year observation period the number of 
persons known with diabetes in Wales increased by 
52 229 from 131 119 in 2007–2008 to 183 348 in 2014–
2015 (table 3) representing an increase in the prevalence 
of diabetes in Wales from 4.3% in 2007–2008 to 5.9% in 
2014–2015. During this time, there was an increase in 
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Table 3 New certifications for SI and SSI due to diabetic retinopathy in those persons with known diabetes in Wales between 
2007 and 2015: n (per 100 000 population)
Time period Total with diabetes Total new certifications SI SSI
2007–2008 131 119 108 (82.4) 64 (48.8) 41 (31.3)
2008–2009 138 988 140 (100.7) 89 (64.5) 51 (36.7)
2009–2010 146 173 118 (80.7) 71 (48.6) 45 (30.8)
2010–2011 153 175 103 (67.2) 62 (40.5) 40 (26.1)
2011–2012 160 533 95 (59.2) 55 (34.3) 38 (23.7)
2012–2013 167 537 98 (58.5) 58 (34.6) 38 (22.7)
2013–2014 173 299 95 (54.8) 62 (35.8) 29 (16.7)
2014–2015 183 348 86 (46.9) 51 (27.8) 29 (15.8)
SI, sight impairment; SSI, severe sight impairment.
Figure 1 Total visual impairment certifications and incidence 
of sight and severe sight impairment due to diabetic 
retinopathy in Wales (per 100 000 PWD). PWD, people with 
diabetes.
the rate of new certifications for SI and SSI combined, 
SI and SSI from the first to the second year (2007–2008 
to 2008–2009) from 82.4 (95% CI 68.2 to 99.4), 48.8 
(95% CI 38.2 to 62.3) and 31.3 (95% CI 23.1 to 42.4) 
to 100.7 (95% CI 85.4 to 118.8), 64.5 (95% CI 52.0 to 
78.8) and 36.7 (95% CI 27.9 to 48.2), respectively, per 
100 000 persons with diabetes. Thereafter, the rate fell to 
46.9 (95% CI 38.0 to 57.9), 27.8 (95% CI 21.2 to 36.6) 
and 15.8 (95% CI 11.0 to 22.7), respectively, per 100 000 
diabetic population a reduction of 53.4%, 56.9% and 
56.9%, respectively, by 2014–2015. The overall reduc-
tion over the entire 8-year study for new certifications in 
persons with diabetes for SI and SSI combined, SI and SSI 
was 43.1%, 43.0% and 49.5%, respectively (figure 1).
dIscussIon
This analysis of new certifications for SI and SSI in Wales 
from 2007–2008 to 2014–2015 provides information on 
the changes that occurred over the 8-year observation 
period due to any cause and specifically DR. Between 
2007 and 2015, the number of new certifications for SI 
and SSI due to DR fell by 23.8% and 35.7%, respectively, 
although there was a slight increase in the second year in 
SI and a smaller increase in SSI during the fifth year. In 
the context of the rising number of persons with diabetes 
(~40%) during the same period of time, the proportion 
of persons with diabetes certified as SI and SSI combined, 
SI or SSI alone almost halved between 2007–2008 and 
2014–2015 at 43.1%, 43.0% and 49.5%, respectively. It 
is acknowledged that a more prolonged period of obser-
vation prior to 2007 would have been most helpful in 
ascertaining the meaningfulness of this important trend 
in lowering of new certification rates for visual impair-
ment in Wales since the introduction of a national DR 
screening service for Wales.
Currently there are a limited number of reports on 
the number of new certifications for SI and SSI due to 
DR/maculopathy. For those that do exist it is difficult to 
compare findings due to different methods for certifi-
cations and definitions of SI and SSI. However, recently 
it was reported that in Ireland there were 33 new certi-
fications including both SI and SSI due to DR in 2007 
decreasing to 29 in 2013 which equates to almost halving 
the risk in persons with diabetes from 45.9 per 100 000 in 
2007 to 26.4 per 100 000 in 2013,22 which is lower than 
seen in our population with diabetes in Wales. It is note-
worthy that in Ireland prior to the establishment of a 
national DR screening programme in 2013, DR screening 
was performed on a limited basis by local services using 
different models of service provision and the analysis 
restricted to the 18–69 years of age population. Earlier, in 
Fife, Scotland, the incidence of blindness due to diabetic 
eye disease during 1990–1999 was reported to be 64 per 
100 000 population/year with diabetes.23 During the 
following decade between 2000 and 2009 the incidence 
of blindness in Scotland fell by a mean of 10.6% per year 
from 59.7 to 23.9 per 100 000 in the diabetes population,24 
which is slightly lower than the 30.8 per 100 000 seen in 
our population in 2009–2010. The Scottish national 
screening programme for DR was implemented in 2006 
mid-way during our study period. A comparison of the 
causes of new SSI certifications in England and Wales in 
working age adults (16–64 years) between 1999–2000 and 
2009–2010 reported a reduction due to DR from 17.7% 
to 14.4% as the main cause and from 17.9% to 16.2% with 
DR as a main or contributory cause.18
In our study, there are a number of possible explana-
tions as to why the number of new certifications of SI and 
SSI due to DR fell during the 8-year period of observation 
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between 2007–2008 and 2014–2015. Screening for DR 
was introduced in Wales in 2003,25 26 along with the 
parallel availability of new treatments for management 
of both diabetes and sight-threatening DR and macu-
lopathy.27–30 In addition, an increase in the population 
with diabetes during this period will also contribute to 
this observation due to the greater awareness of diabetes 
and changes in diagnostic criteria. To date, relatively few 
studies have reported a reduction in the prevalence of 
sight-threatening DR mainly referring to persons with 
type 1 diabetes,31–33 again suggesting the possible benefit 
of recent changes in the management of diabetes. In 
addition, a systematic review of 28 studies noted that 
participants involved from 1986 onwards had a lower 
proportion of proliferative DR and severe vision loss at 
2.6% and 3.2%, respectively, compared with 1985 and 
before at 19.5% and 9.7%, respectively.31 These studies 
suggest that the reduction in sight-threatening DR could 
possibly be due to improved diabetes and/or ophthalmo-
logical care. In our experience in Wales, the number of 
people referred by the DESW to the hospital eye services 
with sight-threatening DR for ophthalmological review fell 
from 3.4% in 2007 to 2.0% in 2015.34 There has also been 
a decrease in the volume of certifications in England and 
Wales especially of partially sighted people and also there 
is evidence to suggest an inappropriate SSI certification 
rate of approximately 20%, due to a variety of reasons.35 36 
Implementation of the national DR screening service will 
have resulted in a reduction in SSI as a result of the 
earlier referral and treatment of sight-threatening DR by 
the hospital eye services. In addition, providing awareness 
of the presence of DR to primary care indicates the need 
for reviewing diabetes management in order to prevent 
progression of non-sight-threatening DR. It would be 
difficult to say if one or any one of these changes were 
primarily responsible for the observed decrease as it is 
more likely to be a combination of these elements.
Using certifications to study rates of SI is justified on 
the grounds of coverage and the collection of uniform 
data fields and working definitions of visual impairment 
both partially sighted and blindness. However, there are 
major limitations which are well described by others14–16 
acknowledging the fact that certification is hospital and 
not population based which requires the patient to access 
hospital-based services in order to be seen and certified by 
a consultant ophthalmologist. A substantial proportion of 
visually impaired persons (approximately 50%) remains 
uncertified and certification is deemed inappropriate in 
approximately 23%.15 32 34 Patient and healthcare profes-
sional knowledge and attitude relating to certification for 
visual impairment can also have a negative impact. Under-
standably, the offer of certification can be distressing for 
patients and they may therefore need time to come to 
terms with this realisation as well as understanding the 
important benefits certification may bring.17 Ophthalmol-
ogists can be uncertain as to when to offer certification, 
which results in unnecessary delay between the diagnosis 
of certifiable sight loss and the offer of certification with 
a bias towards SSI, permanent, non-treatable causes, 
and those with the central rather than peripheral vision 
loss.37 38 Our analysis provides data on the incidence of 
new certifications for SI and SSI in Wales as a result of DR 
over an 8-year period since the introduction of a nation-
wide DR screening service (DESW). The findings need to 
be interpreted acknowledging the inherent limitations of 
the current state of visual impairment certifications where 
unfortunately blind certification does not equate with 
blindness rates. Due to these limitations and different 
definitions of SI and SSI in other countries and settings, it 
would be difficult to apply these findings to other settings 
outside of the UK.
Trends in SI and SSI certifications due to DR are clearly 
decreasing in Wales as in other regions of the UK,18 22 24 
although the reasons need to be more fully elucidated 
and confirmed with further analysis over the coming 
years. Studies have also indicated that those persons most 
at risk of losing vision due to DR either do not attend 
for eye screening and/or are not fully engaged with the 
management of their diabetes.39–43 In order to ensure the 
reduced risk for sight loss due to DR in Wales continues, 
more needs to be done to improve attendance rates for 
eye screening above its current and stable level at approx-
imately 80%. Studies are currently under way to explore 
this very important question and to ensure a better uptake 
into the screening services in order to accommodate this 
vulnerable segment of the population of people with 
diabetes. Increased access to structured diabetes educa-
tion programme is another essential way to help those 
with diabetes to better understand the importance of 
regular DR screening and the need to achieve and main-
tain good glycaemic, blood pressure and lipid control.
In conclusion, findings from this analysis provide posi-
tive and useful epidemiological information to assist in 
the future monitoring of diabetic eye disease in order to 
provide the basis for assessing the benefit or otherwise 
of changes in the management of diabetes and DR/
maculopathy. However, improvements are needed to the 
certification process to enhance its value by providing reli-
able and meaningful epidemiological data in support of 
the eventual aim of eradicating preventable vision threat-
ening disease in the ever increasing population of people 
with diabetes and the general population alike. This 
analysis, despite the inherent limitations of the current 
process for the CVI, highlights the positive benefits of 
introducing a community-based screening programme 
for the early detection of sight-threatening DR.
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